Bayer’s €300 Million Eye Implant Deal Comes as Quarterly Cash Outflow Hits €2.3 Billion

Bayer posts €2.32B negative free cash flow from legal settlements, acquires Perfuse for $300M to bolster ophthalmology pipeline amid Eylea decline.

Bayer’s first-quarter results laid bare a familiar tension: operational strength in agribusiness and a promising pipeline in pharma are being overshadowed by a relentless cash drain from legal settlements. The company posted a negative free cash flow of €2.32 billion during the period, with roughly €2 billion tied to payouts in glyphosate and PCB lawsuits in the United States. Net financial debt stood at €32.52 billion as of March 31.

Against that backdrop, the German conglomerate struck a deal to acquire Perfuse, a specialist in ocular implants, for an upfront payment of $300 million. Additional milestone payments could reach $2.15 billion. The move is a direct response to the erosion of Eylea, a once-dominant eye drug that saw first-quarter revenue slide 24 percent to €623 million as biosimilars eat into its market share and pricing power.

The Perfuse implant, known as PER-001, is designed to give Bayer a new foothold in ophthalmology as it faces patent headwinds on both Eylea and the blood thinner Xarelto. Chairman Bill Anderson described the acquisition as part of a broader strategy to shore up the pharma pipeline, though the short-term margin impact of increased R&D and marketing spending remains a drag.

Crop Science delivers a strong, if one-off, boost

The company’s agribusiness division, however, provided a bright spot. Segment revenue rose 6.8 percent on a currency-adjusted basis to €7.6 billion, driven by robust demand for soybean and corn seeds as well as recovering prices for the herbicide dicamba. EBITDA before special items climbed 17.9 percent to €3.01 billion, helped by a €448 million licensing settlement with Corteva that resolved a North American legal dispute.

Underlying volumes for glyphosate-based products declined on a currency-adjusted basis, meaning the Corteva windfall masked what would have been a less comfortable performance in Crop Science. Still, the division’s profit jump helped lift group revenue to €13.4 billion, a currency-adjusted increase of 4.1 percent.

Pharma pivots to Nubeqa as old blockbusters fade

Yet the pharma division tells a more nuanced story. Total segment EBITDA fell 7.5 percent to €1.24 billion, though the drop was milder than analysts had feared. Nubeqa emerged as a key growth driver, posting a 57 percent sales surge to €749 million, while Kerendia jumped 84 percent. But those gains remain insufficient to fully offset the decline from Xarelto and Eylea, both of which face patent cliffs.

Investors are now turning their attention to a pivotal court ruling. The U.S. Supreme Court is expected to issue a decision on glyphosate liability by the end of June, a verdict that could remove a valuation discount that has weighed on Bayer shares for years. JPMorgan maintains an “Overweight” rating with a €50 price target, citing easing currency headwinds. Barclays also rates the stock “Overweight” with a €48 target, pointing to the improved profitability in Crop Science. MWB Research sees fair value at €52, highlighting the operational leverage in the agricultural business.

Bayer shares traded at €38.29 in early Wednesday dealings, roughly 22 percent below their February high of €49.17. On a twelve-month view, the stock has still gained more than 54 percent. Anderson reiterated the full-year outlook of revenue between €44.5 billion and €46.5 billion and adjusted earnings per share of €4.10 to €4.60, though nominal adjustments were required to account for currency effects. The Perfuse deal signals ambition in pharma, but the balance sheet demands discipline—and the next quarterly free cash flow number will be watched closely.